Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial

JAMA

Volumn 292, Issue 6, 2004, Pages 696-703

  Lincoff, A Michael ^a   Kleiman, Neal S ^b   Kereiakes, Dean J ^c   Feit, Frederick ^d   Bittl, John A ^e   Jackman, J Daniel ^f   Sarembock, Ian J ^g   Cohen, David J ^h   Spriggs, Douglas ⁱ   Ebrahimi, Ramin ^j   Keren, Gadi ^k   Carr, Jeffrey ^l   Cohen, Eric A ^m   Betriu, Amadeo ⁿ   Desmet, Walter ^o   Rutsch, Wolfgang ^p   Wilcox, Robert G ^q   De Feyter, Pim J ^r   Vahanian, Alec ^s   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c The Carl & Edyth Lindner Center for Research & Education   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Munroe Regional Med Center   (United States)

^f Trinity Mother Frances Hospitals and Clinics   (United States)

^g UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ Clearwater Cardiovascular Consultants   (United States)

^j VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^k TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^l EAST TEXAS MEDICAL CENTER   (United States)

^m SUNNYBROOK RESEARCH INSTITUTE   (Canada)

ⁿ HOSPITAL CLÍNIC   (Spain)

^o UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^p CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^q NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^r ERASMUS MEDICAL CENTER   (Netherlands)

^s BICHAT HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; HEPARIN; HIRULOG; PYRIDINE DERIVATIVE; THIENOPYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; HIRUDIN DERIVATIVE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PEPTIDE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART MUSCLE REVASCULARIZATION; HEPARINIZATION; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; REOPERATION; RISK FACTOR; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS; DRUG ANTAGONISM; MIDDLE AGED; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HIRUDINS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 3843060250     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.6.696     Document Type: Article

References (23)

1. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998;339:1665-1671.
2. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronaryt stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet. 1998;352:87-92.
3. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356:2037-2044.
4. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa blockade in coronary artery disease. J Am Coll Cardiol. 2000;35:1103-1115.
5. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ, on behalf of the Bivalirudin Angioplasty Study Investigators. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142:952-959.
6. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J. 2002;143:847-853.
7. Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol. In press.
8. White H, for the Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001;358:1855-1863.
9. Weitz JI, Bates ER. Direct thrombin inhibitors in cardiac disease. Cardiovasc Toxicol. 2003;3:13-25.
10. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: the REPLACE-2 randomized trial [published correction appears in JAMA. 2003;289:1638]. JAMA. 2003;289:853-863.
11. Antman EM. Should bivalirudin replace heparin during percutaneous coronary intervention? JAMA. 2003;289:903-905.
12. Abdelmeguid AE, Ellis SG, Sapp SK, Whitlow PL, Topol EJ. Defining the appropriate threshold of creatine kinase elevation after percutaneous interventions. Am Heart J. 1996;131:1097-1105.
13. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. JAMA. 1997;278:479-484.
14. Lincoff AM, Tcheng JE, Califf RM, et al. Sustained supression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one year outcome in the EPILOG trial. Circulation. 1999;99:1951-1958.
15. Topol EJ, Mark DB, Lincoff AM, et al. Enhanced survival with platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: one year outcomes and health care economic implications from a multicenter, randomized trial. Lancet. 1999;354:2019-2024.
16. Anderson KM, Califf RM, Stone GW, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2001;37:2059-2065.
17. Feit F. Bivalirudin: bleeding analysis of REPLACE-2 [TCTMD Webcast series]. New York: NY: Cardiovascular Research Foundation. Presented at ACUITY Webcast Series; April 26, 2004. Available at: http://tctmd.com/descwebcasts/one. html?webcast_id=301.
18. Kereiakes DJ, Lincoff AM, Anderson KM, et al. Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. Am J Cardiol. 2002;90:628-630.
19. Ellis SG, Roubin GS, Wilentz J, Douglas JS, King SB. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J. 1989;117:777-782.
20. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-1894.
21. Lincoff AM, Califf RM, Anderson KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by c7E3 Fab (abciximab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol. 1997;30:149-156.
22. PRISM PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-1497.
23. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.